VALUE-BASED PURCHASING AGREEMENTS FOR PHARMACEUTICALS HAVE BEEN DIFFICULT TO IMPLEMENT IN MEDICAID. A NEW BILL IN THE HOUSE AIMS TO CHANGE THAT.
The Medicaid VBP Act, released Tuesday, aims to ensure new treatments such as gene therapies would be administered under Medicaid via a value-based agreement that reimburses drug makers based on the outcomes the drug provides….Read more here>>
The legislation drew plaudits from payer groups who have claimed that regulatory barriers are hurting movement towards paying for drugs based on their outcomes.
“VBPs are a critical tool to make sure we only pay for prescription drugs that work,” said Joel White, president of the advocacy group Council for Affordable Health Coverage, which aims to cut healthcare costs and counts several payers, drug manufacturers and pharmacy chains among its membership.